Even if all stage IV NSCLC cases (squamous and non-squamous) are recommended for programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) testing, the test was not assessed in 29 patients. This evidence concerns the gene CD274 and non-small cell lung carcinoma.